Primary headache disorders are idiopathic clinical entities in which the headache itself constitutes the primary pathological process rather than a symptom of an underlying structural or systemic lesion
1. Migraine (ICHD-3 Group 1)
Migraine is a common neurological disorder characterized by episodic paroxysms of headache accompanied by autonomic and neurological symptoms
Diagnostic Criteria Breakdown
1.1 Migraine Without Aura
: A. At least 5 attacks fulfilling criteria B–D
. B. Attack duration of 4–72 hours (untreated or unsuccessfully treated)
. C. Headache has at least two of the following four features:
Unilateral location
Pulsating quality
Moderate or severe pain intensity
Aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs)
.
D. Accompanied by at least one of the following during the headache:
Nausea and/or vomiting
Photophobia and phonophobia
.
E. Not better accounted for by another ICHD-3 diagnosis
.
1.2 Migraine With Aura
: Requires at least 2 attacks characterized by fully reversible focal neurological symptoms (visual, sensory, speech/language, motor, brainstem, or retinal)
. Aura criteria require at least one aura symptom spreading gradually over $\ge$5 minutes, individual symptoms lasting 5–60 minutes, unilateral distribution, and headache onset accompanying or following the aura within 60 minutes
.
1.3 Chronic Migraine
: Defined as headache occurring on $\ge$15 days per month for >3 months, where at least 8 days per month meet criteria for migraine (or are relieved by a triptan/ergot derivative) in a patient with a baseline history of episodic migraine
.
2. Tension-Type Headache (ICHD-3 Group 2)
Tension-type headache is the most prevalent primary headache disorder worldwide, characterized by featureless, mild-to-moderate, bilateral head pressure
TTH Diagnostic Subtypes
Infrequent Episodic TTH: $<1$ day per month ($<12$ days/year)
. Frequent Episodic TTH: 1–14 days per month for $>3$ months ($\ge 12$ and $<180$ days/year)
. Chronic TTH: $\ge 15$ days per month for $>3$ months ($\ge 180$ days/year)
.
Core Clinical Characteristics of TTH Attacks
Duration: 30 minutes to 7 days (or unremitting in chronic forms)
. Pain Quality: Bilateral, pressing or tightening (non-pulsating) quality of mild-to-moderate intensity
. Physical Activity Effect: Not aggravated by routine physical activity
. Associated Features: Absence of nausea or vomiting; no more than one of photophobia or phonophobia
.
3. Trigeminal Autonomic Cephalalgias (ICHD-3 Group 3)
TACs are characterized by strict unilateral headache accompanied by prominent ipsilateral cranial autonomic features
Trigeminal Autonomic Cephalalgias (TACs)
├── 3.1 Cluster Headache
├── 3.2 Paroxysmal Hemicrania
├── 3.3 Short-lasting Unilateral Neuralgiform Headache Attacks (SUNCT / SUNA)
└── 3.4 Hemicrania Continua
| TAC Entity | Attack Duration | Attack Frequency | Absolute Indomethacin Response |
3.1 Cluster Headache | 15–180 minutes | 1 every other day to 8 per day | No |
3.2 Paroxysmal Hemicrania | 2–30 minutes | >5 per day for >50% of time | Yes (Absolute response) |
3.3 SUNCT / SUNA | 1–600 seconds | $\ge 1$ per day (stabs or saw-tooth) | No |
3.4 Hemicrania Continua | Continuous (>3 months) | Continuous with exacerbations | Yes (Absolute response) |
Note on Cranial Autonomic Features: TACs share ipsilateral signs including conjunctival injection, lacrimation, nasal congestion, rhinorrhea, eyelid edema, forehead/facial sweating, miosis, or ptosis
Key Takeaways for Differential Diagnosis
Migraine vs. TTH: Migraine is pulsating, unilateral, aggravated by movement, and accompanied by nausea/vomiting or photophobia/phonophobia; TTH is bilateral, pressing, unaffected by activity, and lacks significant nausea
. Indomethacin Sensitivity: Paroxysmal Hemicrania and Hemicrania Continua require absolute prevention/resolution by therapeutic doses of indomethacin for diagnosis
. SUNCT vs. SUNA: SUNCT requires both conjunctival injection and lacrimation, whereas SUNA requires only one or neither
.